Evidence map›Paper›PMID 30394825›Full record

ArticleJournal of the renin-angiotensin-aldosterone system : JRAAS

Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.

Marine Lallemant, Sarah Prévost, François Nobili, Didier Riethmuller, Rajeev Ramanah, Marie-France Seronde, Nicolas Mottet

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the renin-angiotensin-aldosterone system : JRAAS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Marine Lallemant1 Obstetrics and Gynaecology Department, Besançon University Medical Centre, Franche-Comté University, France.ORCID https://orcid.org/0000-0002-3341-5267
Sarah Prévost1 Obstetrics and Gynaecology Department, Besançon University Medical Centre, Franche-Comté University, France.
François Nobili2 Paediatric Nephrology Department, Besançon University Medical Centre, Franche-Comté University, France.
Didier Riethmuller1 Obstetrics and Gynaecology Department, Besançon University Medical Centre, Franche-Comté University, France.
Rajeev Ramanah1 Obstetrics and Gynaecology Department, Besançon University Medical Centre, Franche-Comté University, France.
Marie-France Seronde3 Cardiology Department, Besançon University Medical Centre, Franche-Comté University, France.
Nicolas Mottet1 Obstetrics and Gynaecology Department, Besançon University Medical Centre, Franche-Comté University, France.
Université de franche-comté · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of prenatal exposure to angiotensin II receptor antagonists (ARA II) from the beginning of pregnancy in a patient with a hypokinetic dilated cardiomyopathy. This case report emphasizes the fetal renal impact of prolonged intrauterine exposure to renin-angiotensin system (RAS) blockers, and highlights that this exposure can cause severe prenatal hypocalvaria. This delayed ossification can be reversible after birth, but the presence of anhydramnios indicates an early and irreversible block of RAS blockers in the fetus that is responsible for fetal kidney development abnormalities. This association carries a high risk of neonatal death. Prolonged exposure to ARA II or other RAS blockers remains prohibited throughout pregnancy.

Indexed as

AdultAngiotensin II Type 2 Receptor BlockersCalcinosisFatal OutcomeFemaleFetusHumansImage Processing, Computer-AssistedMaleMaternal ExposurePregnancySkullAngiotensin II Type 2 Receptor Blockersangiotensin-converting enzyme inhibitorsangiotensin II receptor antagonistsanhydramniosfetushypocalvariaRenin-angiotensin system blockers

Identifiers

PMID30394825
PMCPMC6243420
OpenAlexW2900408056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.